Xbrane Biopharma AB (XBRANE ST) stock market data APIs
kr13.0427
1(7.7%)
as of November 2, 2026
Try our APIs with
free plan!
Xbrane Biopharma AB Financial Data Overview
Price chart is built with
Anychart
Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. It offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults. The company also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; and Xdarzane, a daratumumab biosimilar targeting CD38 for the treatment of multiple myeloma. The company has a strategic partnership with JOINN Biologics US Inc. to provide customized development services for Xdarzane, Xbrane´s biosimilar candidate referencing Darzalex. The company was incorporated in 2008 and is headquartered in Solna, Sweden.
Prev. Close
13.0427
Open
14.0396
High
14.2708
Low
12.1331
52 wk Range
5.421-20
Market Cap
264 M
Shares Outstanding
20 605 K
Revenue
128 M
EPS
-0.554
Beta
0.775
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Xbrane Biopharma AB data using free add-ons & libraries
Get Xbrane Biopharma AB Fundamental Data
Xbrane Biopharma AB Fundamental data includes:
- Net Revenue: 128 M
- EBITDA: -48 483 000
- Earnings Per Share: -1
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-07-20
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Xbrane Biopharma AB News
New
3 European Growth Companies With Insiders Owning Up To 12%
As European markets continue to show resilience, with the pan-European STOXX Europe 600 Index and major stock indexes experiencing gains, investors are increasingly focused on identifying growth oppor...
3 European Growth Stocks With High Insider Ownership Expecting Up To 70% Earnings Growth
As European markets navigate a mixed landscape, with the pan-European STOXX Europe 600 Index slightly up and major indexes showing varied performances, investors are closely watching growth companies ...
3 European Growth Companies Insiders Are Heavily Investing In
As European markets navigate a mixed landscape marked by dovish signals from the U.S. Federal Reserve and fluctuating industrial outputs, investors are increasingly focusing on growth companies with s...
European Growth Stocks With Significant Insider Stakes
As European markets experience a mixed performance, with the pan-European STOXX Europe 600 Index seeing a modest rise amid dovish signals from the U.S. Federal Reserve, investors are closely watching ...
Get Xbrane Biopharma AB fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.